State Street’s Regencell Bioscience RGC Stock Holding History

State Street’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,851	Closed	-$301K	–	4254
2026 Q1	$301K	Buy	+11,851	New	+$335K	﹤0.01%	3782

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

State Street's RGC Position: Q2 2026 in Review

State Street sold out of Regencell Bioscience (RGC) in Q2 2026, closing a stake of 11,851 shares — an estimated $301K sold.

State Street first reported a position in RGC in Q1 2026 and held it in 1 quarter. The position peaked at $301K in Q1 2026. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

State Street reported no remaining Regencell Bioscience position as of Q2 2026 after selling out during the quarter.
State Street sold 11,851 Regencell Bioscience shares in Q2 2026, an estimated $301K.
State Street first reported a position in Regencell Bioscience in Q1 2026 and held it in 1 quarter.
State Street's Regencell Bioscience position peaked at $301K in Q1 2026.
35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.